TY  - JOUR
A1  - Sauerbruch, Tilman
A1  - Hennenberg, Martin
A1  - Trebicka, Jonel
A1  - Beuers, Ulrich
T1  - Bile acids, liver cirrhosis, and extrahepatic vascular dysfunction
T2  - Frontiers in physiology
N2  - The bile acid pool with its individual bile acids (BA) is modulated in the enterohepatic circulation by the liver as the primary site of synthesis, the motility of the gallbladder and of the intestinal tract, as well as by bacterial enzymes in the intestine. The nuclear receptor farnesoid X receptor (FXR) and Gpbar1 (TGR5) are important set screws in this process. Bile acids have a vasodilatory effect, at least according to in vitro studies. The present review examines the question of the extent to which the increase in bile acids in plasma could be responsible for the hyperdynamic circulatory disturbance of liver cirrhosis and whether modulation of the bile acid pool, for example, via administration of ursodeoxycholic acid (UDCA) or via modulation of the dysbiosis present in liver cirrhosis could influence the hemodynamic disorder of liver cirrhosis. According to our analysis, the evidence for this is limited. Long-term studies on this question are lacking.
KW  - bile acids
KW  - liver cirrhosis
KW  - portal hypertension
KW  - microbiome
KW  - vasodilation
Y1  - 2021
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/62695
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-626951
SN  - 1664-042X
N1  - JT is supported by grants from the Deutsche Forschungsgemeinschaft (SFB TRR57 to P18, CRC 1382AO9), European Union’s Horizon 2020 Research and Innovation Programme (Galaxy, No. 668031, MICROB-PREDICT, No. 825694, and DECISION, No.847949), and Societal Challenges - Health, Demographic Change and Wellbeing (No. 731875), and Cellex Foundation (PREDICT). Wenyi Gu is supported by the China Scholarships Council (CSC: #201906230332). The funders had no influence on study design, data collection, and analysis, decision to publish, or preparation of the manuscript.
VL  - 12
IS  - art. 718783
SP  - 1
EP  - 18
PB  - Frontiers Research Foundation
CY  - Lausanne
ER  -